Can shrinking radiation margins spare lungs without sacrificing cancer control?

NCT ID NCT06542159

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether using real-time adaptive radiation without the usual safety margin can reduce lung side effects in people with early-stage non-small cell lung cancer or limited lung metastases. About 130 participants will be randomly assigned to either standard radiation or the new adaptive technique. The main goal is to see if the new method lowers the chance of breathing problems while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (online adaptive stereotactic body radiotherapy without PTV expansion margin)
What this could lead to: If successful, this approach could reduce breathing-related side effects from radiation while still effectively controlling early-stage lung cancer or limited lung metastases.
What could go wrong: This is a phase II trial with only 130 participants, so results are preliminary. Removing safety margins might increase the risk of missing the tumor, and the technique requires specialized equipment not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADAPTIVE RADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADAPTIVE RADIOTHERAPY LUNG OLIGOMETASTASES NON-SMALL CELL LUNG CANCER STEREOTACTIC BODY RADIOTHERAPY TOXICITY

Contacts and locations

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.